An International, Multicentre, Randomised, Open, Controlled, Two-Parallel Group, Phase II Pilot Study to Evaluate the Efficacy and Safety of ARIXTRA for Anticoagulation of Patients With Atrial Fibrillation Undergoing Electric Cardioversion Following Transesophageal Echocardiography.

Trial Profile

An International, Multicentre, Randomised, Open, Controlled, Two-Parallel Group, Phase II Pilot Study to Evaluate the Efficacy and Safety of ARIXTRA for Anticoagulation of Patients With Atrial Fibrillation Undergoing Electric Cardioversion Following Transesophageal Echocardiography.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Feb 2015

At a glance

  • Drugs Fondaparinux sodium (Primary) ; Fluindione; Heparin; Phenprocoumon; Warfarin
  • Indications Pulmonary embolism; Thromboembolism; Thrombosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SAFE-AF
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 04 Jul 2012 Planned number of patients changed from 350 to 690 as reported in the European Clinical Trials Database record.
    • 04 Jul 2012 Bristol-Myers Squibb, Procter and Gamble, Sanofi added as associations as reported in the European Clinical Trials Database record.
    • 22 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top